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ABSTRACT 
Arterial tortuosity syndrome (ATS) is a rare, autosomal recessively inherited connective tissue 
disorder caused by biallelic loss of function mutations in SLC2A10. While SLC2A10 and its 
product, a class III facilitative glucose transporter (GLUT10), have been implicated in ATS, the 
exact disease mechanism has not been fully elucidated. ATS is characterized by systemic medium 
and large artery lengthening and subsequent tortuosity, which significantly increases affected 
individual’s risk of ischemic and hemorrhagic events as well as aortic dilation and dissection. 
Histologically, fibroblasts and vascular tissue of affected individuals have demonstrated a 
dysregulation of the extracellular matrix proteins, particularly reduced and fragmented elastin 
fibers. While most individuals with ATS possess cutaneous findings characteristic of connective 
tissue disorders, ranging from soft, hyperextensible skin to visibly lax skin in redundant folds, no 
study has quantified differences in the biomechanical properties of the skin between individuals 
with ATS and healthy individuals. In this study, rapid, non-invasive, in vivo cutaneous 
measurements were executed using the DermaLab® Combo SkinLab to determine the functional 
consequences on the skin of systemic ATS in a cohort of 8 individuals, compared to 28 of their 
unaffected relatives. Our affected population demonstrated significantly reduced elastic modulus 
(E) and viscoelastic modulus (VE) when compared to unaffected individuals. Affected individuals 
also exhibited increased skin retraction time. This research significantly impacts public health by 
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Emily Spoth, MS 
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contributing to rare disease research, specifically by further characterizing the natural history of 
ATS and aiding in diagnosing the condition in the general population. 
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1.0  INTRODUCTION 
Arterial tortuosity syndrome (ATS) is a rare connective tissue disorder with approximately 100 
cases reported in the medical literature.1 ATS is caused by biallelic loss of function mutations in 
the SLC2A10 gene, which encodes a III facilitative glucose transporter, GLUT10.2 The primary 
feature of ATS is widespread medium and large artery tortuosity, which predisposes affected 
individuals to aortic aneurysm and dissection as well as other ischemic events.3 Systemic tortuosity 
is diagnosed with vascular imaging, most frequently magnetic resonance angiogram (MRA) but 
echocardiogram, angiography, or computed tomography angiography may also be used.4 Variable 
systemic involvement has been noted in affected individuals, including additional cardiovascular 
anomalies, characteristic craniofacial features, as well as other generalized connective tissue 
disorder findings like soft, hyperextensible skin, hernias, multiple skeletal findings, and ocular 
issues.5 
Numerous studies have demonstrated dysregulation of the extracellular matrix in patients 
with ATS1,2,6, however a single pathological mechanism has not been elucidated. Histologically, 
the fibroblasts and vascular tissue in individuals with ATS have reduced external elastic lamina, 
fragmented internal elastic lamina, and increased collagen deposition.1,7 Most individuals with 
ATS possess cutaneous findings, the severity of which range from thin, hyperextensible skin with 
a velvety texture to significantly loose and lax skin.1 Despite these findings, the biomechanical 
properties of the skin have not been measured in individuals with ATS. Previous studies have 
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characterized significant differences in quantifiable skin properties in other connective tissue 
disorders, like Williams syndrome,8 the cutis laxa family of connective tissue disorders,9 and 
Ehlers-Danlos syndrome.10 In this study, we sought to determine the functional consequences of 
systemic connective tissue disease in individuals affected with arterial tortuosity syndrome by 
measuring physical properties of the skin, including elasticity, viscoelasticity, epidermal 
hydration, and dermal thickness. Unaffected individuals were used as healthy controls.  
We hypothesized that individuals with ATS would have reduced skin elasticity, 
viscoelasticity, and dermal thickness as well as increased skin retraction time, epidermal hydration, 
and collagen intensity compared to healthy controls. To test these hypotheses, we performed in 
vivo measurements using a DermaLab® Combo SkinLab instrument on individuals affected with 
ATS.  
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2.0  LITERATURE REVIEW 
2.1 ARTERIAL TORTUOSITY SYNDROME 
Arterial tortuosity syndrome (ATS) is a rare, autosomal recessively inherited connective tissue 
disorder that was first described in 1967 by Ertugrul who noted widespread arterial tortuosity in a 
ten-year-old female patient and presumed this finding was due to a yet-unnamed congenital elastin 
defect.7 ATS is characterized by an increased risk of aortic aneurysm and dissection secondary to 
this severe systemic arterial tortuosity.11 Arterial tortuosity syndrome is caused by biallelic loss of 
function mutations in the SLC2A10 gene, which encodes a class III facilitative glucose transporter, 
GLUT10.2 Couke and colleagues elucidated that mutations in SLC2A10 are the responsible for 
ATS through homozygosity mapping of consanguineous families affected by ATS in 2003.12 
Histopathologic studies of affected arterial tissue have revealed a reduced external elastic lamina 
and a fragmented internal elastic lamina.1,3,7 These studies began as early as the first description 
of ATS by Ertugrul, who noted reduced and fragmented elastin in an arterial sample from the first 
defined case.7 Most recently, Beyens and colleagues noted disorganization and fragmentation of 
elastin in pulmonary artery biopsies of three affected individuals and an aortic biopsy from one 
affected individual examined. These biopsies, when stained with Picrosirius polarizaition staining 
demonstrated “increased and disorganized collagen deposition compared with the control 
samples.”1  
While the exact prevalence of ATS is unknown, it is widely accepted to fit the definition 
of a rare disease in the United States with around 100 affected individuals reported in the 
literature.1 ATS is believed to occur in less than one in one million live births.11 This may be an 
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underestimate due to high clinical variability, underdiagnosis, and misdiagnosis as other related 
connective tissue disorders, including Loeys-Dietz syndrome (LDS) and cutis laxa (CL).5 For 
example, LDS patients may frequently present with arterial tortuosity, although this tortuosity and 
aneurysm formation is recognized to be less severe than in ATS.13 Additionally, autosomal 
recessive forms of CL caused by mutations in the LTBP4 gene and the FBLN5 gene similarly cause 
generalized connective tissue disorder findings as well as pulmonary artery stenosis.14 However, 
CL does not cause systemic arterial tortuosity. 
ATS has proven to be a difficult disorder to research, not only due to its rarity in the 
population, but also due to its lack of an ideal model organism. While GLUT10 knockout mice 
have been bred to model arterial tortuosity, they exhibit a less severe or even entire lack of 
cardiovascular phenotype compared to humans affected with ATS.15 A slc2a10 knockout zebrafish 
has proven to be a superior phenocopy to human ATS, with embryos possessing a wavy notochord 
and cardiovascular anomalies.16  
2.1.1 CARDIOVASCULAR CHARACTERISTICS 
ATS is named for the abnormal lengthening of the large and medium-sized arteries, including the 
aorta and distributing arteries, which causes the vessels to convolute with bends and twists. ATS 
is specifically characterized by this distinct tortuosity in two or more vessels, as tortuosity of a 
single vessel is more common.7 While any vessel can be affected, the head, neck, and pulmonary 
arteries are most commonly affected.1 Figure 1 demonstrates this tortuosity captured through 
vascular imagining in the aorta and aortic side branches, the thoracic and abdominal aortas, and 
the intracranial arteries from left to right (Figure 1). Tortuosity increases shear stress on the vessel 
walls and inhibits normal blood flow.17 Therefore, arterial tortuosity predisposes affected 
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individuals to aortic and arterial aneurysms, which may result in cerebrovascular accident or aortic 
dissection, significant causes of morbidity and mortality in individuals with ATS.18,19 Several older 
patients and patients with a less severe diverse clinical presentation have been documented.5 
Affected individuals may also suffer from isolated or widespread vessel stenosis.20 Pulmonary 
artery stenosis often presents with pulmonary hypertension. Venous tortuosity has also been 
observed in some patients.21 While not fully elucidated, an alteration in the transforming growth 
factor-ß (TGFß) signaling pathway has been implicated in the mechanism of aberrant 
cardiovascular formation and functioning, akin to the pathophysiology of other connective tissue 
disorders including LDS and CL.16  
 
 
Figure 1. Vascular imaging of individuals affected with ATS 
2.1.2 EXTRACARDIOVASCULAR CLINICAL CHARACTERISTICS 
While extracardiovascular features have been noted in multiple individuals with ATS, no single 
extracardiovascular clinical characteristic is a pathognomic sign of the condition.  
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2.1.2.1 CRANIOFACIAL 
Individuals with ATS may possess characteristic facial features, including an elongated face with 
midface retrusion and micrognathia.20 A high/arched palate is another common, although not 
universal, craniofacial feature among affected individuals.11 Hypertelorism, downslanting 
palpebral fissures, convex nasal ridge, and dental crowding have also been reported in individuals 
with ATS.1 These craniofacial findings are not typically associated with significant complications, 
although small jaw and high palate can contribute to feeding difficulties in infancy, which may 
progress to failure to thrive if not managed appropriately.11 
2.1.2.2 SKELETAL 
Other skeletal features that typically manifest in connective tissue disorders may also be present 
in individuals with ATS. For example, affected individuals may exhibit scoliosis, pectus 
excavatum or pectus carinatum, joint laxity, joint contractures, arachnodactyly, and/or 
camptodactyly.22 
2.1.2.3 OCULAR 
Ocular findings of other connective tissue disorders are also present in ATS, particularly myopia 
and keratoconus.23 Less frequently, keratoglobus has been noted in affected individuals.1 
2.1.2.4 CUTANEOUS 
Beyond skeletal findings, individuals with ATS often exhibit other classic characteristics of 
connective tissue disorders, including soft, hyperextensible skin, hernias (including inguinal and 
abdominal wall hernias as well as sliding hiatal or diaphragmatic hernias), hypotonia, and pelvic 
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organ prolapse.24 Cutaneous findings in ATS are variable, ranging from velvety, hyperextensible 
skin characteristic of connective tissue disorders to noticeably loose and lax skin.1,5 
2.1.2.5 RESPIRATORY 
Infant respiratory distress syndrome, in which a neonate’s lungs are underdeveloped leading to 
respiratory distress, has frequently been observed in the newborn period.25 This initial respiratory 
issue resolves with the proper treatment and has not been shown to have lasting impact on lung 
function.1  
2.1.3 DIAGNOSIS, PROGNOSIS, AND MANAGEMENT 
Around half of individuals with ATS are diagnosed following a cardiovascular finding, ranging 
from a murmur heard on routine exam to spontaneous aortic dissection.1 Onset is congenital, 
although the age of diagnosis may vary based on the severity of the clinical characteristics. 
Diagnostic criteria do not exist for ATS, as the systemic tortuosity is apparent on vascular imaging 
including magnetic resonance angiography (MRA), computed tomography (CT), echocardiogram, 
or angiography.4 Individuals with widespread tortuosity on imaging typically undergo sequencing 
and deletion/duplication analysis of SLC2A10 to molecularly confirm the diagnosis.5 
While the prognosis of ATS has long been considered to be poor with only 40% surviving 
past five years of life,22 the identification of the SLC2A10 gene and increased utilization of 
expanded genetic testing has informed more recent reports suggesting that ATS has a more 
variable expression than previously believed.5 Therefore, affected individuals have been diagnosed 
later in life into the second and third decades.1 
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There is no cure for arterial tortuosity syndrome. Affected individuals require regular 
evaluations to determine what interventions are necessary to their management. These evaluations 
include echocardiograms, vascular imaging, ophthalmic examinations, and evaluation of the 
palate.26 If individuals present with symptoms, lung function imaging and testing as well as 
skeletal imaging may be warranted.11 Several medications may be utilized to reduce stress on the 
arterial walls, including beta-adrenergic blockers, angiotensin-converting enzyme inhibitors, and 
angiotensin II receptor I antagonists.11 Arterial aneurysms and stenoses, including pulmonary 
artery stenosis, frequently require surgical intervention, either surgery, catherization, or a 
transcatheter-surgical procedure.27,28 Potential skeletal issues are treated accordingly by an 
orthopedist and may include orthotics and potentially surgical intervention of the spine.11 
Similarly, eye manifestations are treated by an ophthalmologist and respiratory symptoms by a 
pulmonologist. 
2.1.4 A TWIST OF FATE–ATS 
A Twist of Fate-ATS (ATOF) is an international patient group for ATS. ATOF was established 
by a family that has been significantly impacted by ATS and has been a source of support for other 
families. ATOF has also grown to hold an annual multidisciplinary clinic and educational seminar 
with specialists from multiple fields, including genetics, cardiology, and ophthalmology. Today, 
the mission of ATOF is “to find a cure for arterial tortuosity syndrome, by supporting research, 
education, awareness, and families.”29 
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2.1.5 GENE 
ATS is caused by biallelic, pathogenic loss of function variants in the SLC2A10 gene, located on 
the short arm of chromosome 20. SLC2A10 is comprised of five exons and encodes the class three 
facilitative glucose transporter 10 (GLUT10), a member of the solute carrier family 2. The role of 
SLC2A10 mutations in ATS was initially discovered in 2003 through homozygosity mapping of 
consanguineous ATS families. After identifying a 4.1 Mb region on chromosome 20q13.1, gene 
sequencing revealed homozygous loss of function mutations in the SLC2A10 gene in all the studied 
families.12 Three families in this research were all from the same region in Morocco, leading 
researchers to believe that there may be a founder mutation causing disease in this population. 
There are around nine recurrent mutations observed in affected individuals, notably a single 
nucleotide substitution of a cytidine to a thymidine at position 394 of the SLC2A10 transcript 
(c.394C>T), which results in an arginine to tryptophan amino acid substitution in the protein 
(p.R132W). Some of these recurrent mutations exhibit founder affects ascertained through 
haplotype analysis.21 While several different types of mutations have been observed including 
deletions and nonsense mutations, all causative mutations are loss of function mutations.5 s 
2.1.6 GENE PRODUCT 
ATS is among the few connective tissue disorders where the responsible gene encodes a transport 
protein. GLUT10 is a facilitative glucose transporter that consists of 541 residues and contains 
twelve hydrophobic transmembrane domains.16 Facilitative transporters, or uniporters, aid in the 
movement of impermeable solutes through the cellular membrane down a concentration gradient. 
GLUT10 structurally diverges from other facilitative glucose transporters with a longer exofacial 
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loop between the ninth and tenth transmembrane domains. GLUT10 also lacks both the N-terminal 
dileucine signal that other class III members have and the PESPR motif in loop six that all other 
GLUTs possess.30 These differences have led researchers to suggest that GLUT10 may perform 
additional roles beyond the typical scope of other members of facilitative glucose transporters. 
GLUT10 has shown expression in multiple organs including the heart, liver, pancreas, lung, brain, 
skeletal muscle, and placenta.31 In more specific ATS studies, GLUT10 expression has been 
identified in the aortic smooth muscle cells and adipocytes.32 Previously, SLC2A10 was identified 
as potential candidate gene for noninsulin-dependent diabetes mellitus through genome wide 
association studies due to GLUT10’s role as a glucose transporter.33 However, several studies have 
shown that mutations in SLC2A10 do not result in a higher incidence of diabetes mellitus.5,34 
2.1.7 PATHOPHYSIOLOGY 
The solute carrier group of transport proteins typically localize to the cell membrane and many of 
their solutes have been identified; however, the exact cellular location and substrates of GLUT10 
have only been partially elucidated, making the pathophysiology of ATS difficult to definitively 
ascertain.35 GLUT10 deficiency has been associated with increased transforming growth factor ß 
(TGFß) signaling in the arterial wall, which has also been noted in Loeys-Dietz syndrome (LDS). 
This observation has been implicated in the phenotypic similarities between ATS and LDS.2 
Several studies have further explored these unknown factors in an attempt to determine the 
mechanism of ATS, detailed below. 
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2.1.7.1 TRANSFORMING GROWTH FACTOR ß SIGNALING 
The TGFß signaling pathway is essential for embryonic development and a multitude of cellular 
processes including growth, differentiation, and apoptosis.36 Importantly, TGFß has also been 
shown to be an essential inhibitor of angiogenesis and enhancer of blood vessel maturation.37 The 
pathway consists of a superfamily of ligands, including bone morphogenetic proteins, growth and 
differentiation factors, anti-mullerian hormone, activin, nodal, and TGFß, binding to a superfamily 
of five receptors, specifically serine/threonine receptor kinases.38 The activated receptors then 
phosphorylate receptor-regulated SMADs which bind to SMAD4, a common signaling transducer. 
The subsequent complexes act as transcription factors in the nucleus, regulating gene expression. 
Increased TGFß signaling has been implicated in the vascular pathogenesis of LDS, which shares 
clinical features with ATS, namely systemic arterial tortuosity and a high risk for aortic aneurysm 
and dissection.39 However, gene expression and molecular rescue studies in a zebrafish model of 
ATS indicated decreased TGFß signaling through embryonic development.16 Thus, increased 
TGFß signaling in postnatal vessels may represent a compensatory rather than pathogenic process.  
2.1.7.2 GLUCOSE-DEPENDENT GENE EXPRESSION 
Facilitative glucose transporters (GLUTs) are so named as glucose has been implicated as their 
primary substrate. Mutations in other SLC genes, which encode for other GLUTs, have been 
implicated in health conditions caused by dysregulation of glucose metabolism. For example, 
biallelic mutations in SLC2A2 which encode for glucose transporter 2 (GLUT2) are responsible 
for Fanconi-Bickel syndrome, a glycogen storage disorder.40 In ATS, researchers have observed 
decreased glucose levels within fibroblasts. This decreased intracellular glucose level is believed 
to affect gene expression of decorin, which directly influences TGFß signaling. Decorin is a 
proteoglycan which associates with connective tissue fibers that inhibit TGFß signaling. This 
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hypothesis is supported by evidence of increased phosphorylation and nuclear translocation of 
Smad2 and connective tissue growth factor as well as decreased decorin expression in vascular 
smooth muscle cells. Of note, the same changes between individuals with ATS and healthy 
controls was not noted in fibroblast cells.2 This data is correlative, and it remains unclear whether 
the observed molecular changes contribute to the disease, are casually unrelated markers of the 
disease, or represent compensatory changes to counteract disease progression. 
2.1.7.3 DEHYDROASCORBIC ACID TRANSPORT IN THE MITOCHONDRIA 
Despite evidence to suggest decreased intracellular glucose levels, circulating glucose and insulin 
levels have historically been normal in affected individuals.5 Therefore, the sub-tracellular location 
of GLUT10 has been closely examined to determine if there may be an alternate pathogenic 
mechanism of ATS. GLUT10 was found to localize to the mitochondria, specifically in the smooth 
muscle cells of the aorta as well as insulin-stimulated adipocytes. When stimulated by insulin, 
GLUT10 localizes to the Golgi apparatus and then to the mitochondria. As glycolysis is localized 
to the cytoplasm, rather than the mitochondria, and glucose is not used for any known biochemical 
reactions in the mitochondria, it is likely that GLUT10 does not transport glucose into the 
mitochondria. Instead, researchers found that GLUT10 transported dehydroascorbate, the oxidized 
form of vitamin C (ascorbate) to mitochondria, increasing intracellular ascorbate levels.32 
Dehydroascorbic acid is thought to be reduced to ascorbate in the mitochondria and released to the 
cytoplasm through an as yet unidentified transporter. This putative ascorbate recycling pathway is 
hypothesized to be especially important in species that lack gulonolactone oxidase, an enzyme 
responsible for the synthesis of ascorbate. These species, including humans, guinea pigs, and fish, 
are unable to synthesize their own vitamin C and rely on diet for this essential antioxidant and 
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enzyme cofactor. This difference in ascorbate metabolism explains the severe vascular 
manifestations of GLUT10 deficiency in humans2 and fish16 but not in mice.15  
Ascorbate protects cells from reactive oxygen species due to its strong reducing capacity.41 
This hypothesis was supported by reduced mitochondrial dehydroascorbate in higher oxidative 
stress conditions along with increased reactive oxygen species levels, mitochondrial fragmentation 
and dysfunction, and increased cell proliferation and migration in aortic smooth muscle cells and 
in arteries from mice homozygous for a G128E missense mutation in GLUT10,32,42 which impairs 
mitochondrial targeting. The G128E mutant mice were consistent with mild arterial disease, only 
developing increased blood pressure with age as opposed to severe arterial tortuosity.42 
2.1.7.4 DEHYDROASCORIBIC ACID TRANSPORT IN THE ENDOPLASMIC 
RETICULUM 
Based on the previous findings supporting the possibility of GLUT10 as a dehydroascorbic acid 
transporter, other researchers have further theorized that GLUT10 may also function in the 
endoplasmic reticulum. Defective dehydroascorbic acid transport was demonstrated in ATS 
fibroblast endomembranes, causing researchers to postulate a role for ascorbic acid in the 
production of extracellular matrix proteins in addition to its mitochondrial function. Ascorbic acid 
is a cofactor for the prolyl hydroxylases, a group of enzymes involved in the post-translational 
modification of prolines which are abundant in extracellular matrix proteins including collagen 
and elastin. Therefore, a defect in transport causing a shortage of ascorbic acid may lead to 
impaired function of extracellular matrix proteins, which has been widely observed in ATS 
fibroblasts.43 Proline hydroxylation has been long known to be essential for the stability of 
collagen.44 The functional importance of the hydroxylation of prolines in elastin is less well 
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understood, however, the non-random nature45 and disease-association of altered proline 
hydroxylation have been previously characterized.46 
2.2 BIOMECHANICAL PROPERTIES OF THE SKIN 
The skin’s unique biomechanical properties are primarily influenced by the extracellular matrix 
proteins of the dense irregular connective tissue that make up the dermis, the layer of skin between 
the epidermis and the subcutaneous tissues. Specifically, this dense irregular connective tissue 
makes up the reticular region of the dermis, a thick layer that lies below the papillary region, the 
other layer of the dermis that is comprised of loose areolar connective tissue.   Collagen is the main 
structural component of the reticular dermis comprising around 77% of the weight of the skin, as 
it is rigid and possesses high tensile strength to resist tearing.47 Conversely, elastin provides 
elasticity to connective tissue due to its flexible, resilient properties. During movement, the ground 
substance, comprised of proteoglycans, is the lubricant between collagen and elastin, but it does 
not heavily contribute to either the tensile strength or elasticity of the skin.47 A basement membrane 
and type VII collagen fibrils anchor the epidermis to the dermis. The primary source of these 
extracellular matrix proteins are fibroblasts, large, spindle or star-shaped cells that are the main 
cell type in connective tissue. While skin fibroblasts from individuals affected with ATS have 
shown significantly reduced and fragmented elastin fibers,35 any potential effects of this on the 
biomechanical properties of the skin have yet to be characterized in vivo.  
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2.2.1 VISCOELASTICITY 
The elastic property of materials resists deformation in response to external forces and returns the 
material to its original shape upon removal of the force. Solids generally behave live elastic 
materials and the stiffness of such materials is quantified by the elastic modulus, also known as 
Young’s modulus. Viscoelasticity also resists against deformation by forces, but the deformation 
is not reversed in viscous material upon removal of the force. Viscosity is generally the property 
of liquids. Many natural materials, including the skin, possess both elastic and viscous properties 
and are hence considered to be viscoelastic. The collagen and elastin fibers which allow for this 
viscoelasticity have been extensively studied in vitro to determine their mechanics, including 
elastic limit.48 The time it takes the skin to return to its baseline after being stressed or stretched is 
referred to as retraction time. The longer the retraction time, the more viscous and less elastic the 
material is. Retraction time has historically been used as a rapid assessment of acute illnesses, like 
dehydration, as well as chronic issues with viscoelasticity.49 
2.2.2 ADDITIONAL QUANTIFIABLE SKIN PROPERTIES 
2.2.2.1 HYDRATION 
Skin moisture is an important component in many of the skin’s primary functions, largely as a 
protective barrier from exogenous environmental harms as well as its role in thermoregulation. 
Epidermal hydration is maintained as the stratum corneum, the outermost layer of the epidermis, 
retains water. The stratum corneum typically consists of ten to thirty percent water, with ten 
percent being the minimum amount required to maintain its supple and flexible nature.50 Keratin 
within the stratum corneum prevents water evaporation.  Epidermal hydration is also dependent 
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upon the maintenance of evaporative loss through water supplied by the bottom layers of the 
epidermis, the dermis, and the sebaceous glands.51 Several external factors can greatly influence 
skin hydration including an individual’s water intake and use of skin moisturizers and some 
intrinsic factors including age and sex have also been implicated.52 Maintaining skin hydration is 
essential for cell proliferation and differentiation, and is further increased by pathological 
processes such as inflammation.53 
2.2.2.2 DERMAL THICKNESS 
Overall skin thickness is influenced by several factors including sex and age and also varies widely 
between different areas of the body. This is particularly true of epidermal thickness, while dermal 
thickness remains more consistent throughout different parts of the body, around 1.1 millimeters. 
Males typically have greater skin thickness than females due to increased collagen density54 and 
skin thickness declines with age due to decreased collagen and ground substance synthesis and 
maintenance. 
2.2.3 PREVIOUS CHARACTERIZATIONS 
Cutaneous findings, including inelastic skin, have been noted in several connective tissue 
disorders. In vivo studies have demonstrated altered biomechanical properties of the skin 
specifically in Ehlers-Danlos syndrome, Williams syndrome, scleroderma, and cutis laxa as well 
as skeletal dysplasias including osteogenesis imperfecta.48 In individuals affected with Williams 
syndrome, which presents with stenosis of the great arteries, but no widespread arterial tortuosity, 
had significantly reduced viscoelastic and elastic moduli compared to healthy controls.8 In 
individuals with cutis laxa, a disease characterized by visually lax and loose skin,, he elastic and 
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viscoelastic moduli are even more markedly reduced than in Williams syndrome. In addition, the 
retraction time is greatly increased.9 To date, similar in vivo cutaneous studies have not been 
performed to determine differences between individuals affected with ATS and healthy controls. 
This study aims to determine what, if any, differences in the quantifiable cutaneous properties of 
elasticity, retraction time, hydration, and thickness exist among individuals affected with ATS and 
healthy controls.  
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3.0  MANUSCRIPT 
3.1 BACKGROUND 
Arterial tortuosity syndrome (ATS) is a rare connective tissue disorder caused by biallelic 
mutations in the SLC2A10 gene, which encodes for a facilitative glucose transporter GLUT10. The 
characteristic feature of ATS is systemic arterial tortuosity of the medium and large vessels, 
conferring a high lifetime risk of ischemic and hemorrhagic events, mainly caused by the rupture 
of aneuryms.5 There is variable expression of a number of other features, including other 
cardiovascular anomalies, craniofacial features, and generalized findings characteristic of 
connective tissue disorders. For example, most individuals affected with ATS exhibit cutaneous 
findings consistent with other connective tissue disorders.1 Cutaneous features similarly exhibit 
variable expression, ranging in severity from velvety, hyperextensible skin to significantly loose 
or lax skin. In additional to external cutaneous features, histological studies of affected vascular 
tissue have demonstrated reduced external elastic lamina and fragmented internal lamina.21 No 
study has attempted to quantify the effect of these external and internal cutaneous findings on the 
biomechanical properties of the skin in individuals affected with ATS.  
In this study, we sought to determine the functional consequences of systemic connective 
tissue disease in individuals affected with arterial tortuosity syndrome by measuring physical 
properties of the skin, including elasticity, viscoelasticity, epidermal hydration, and dermal 
thickness. We hypothesized that individuals with ATS would have reduced skin elasticity, 
viscoelasticity, and dermal thickness as well as increased skin retraction time, epidermal hydration, 
and collagen intensity compared to healthy controls.  
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3.2 METHODS 
To investigate potential differences in biomechanical and quantifiable properties of the skin, we 
performed several noninvasive in vivo skin measurements with a verified instrument, the Coretex 
DermaLab® Combo, in individuals with ATS and their unaffected relatives. This instrument is 
equipped with a variety of probes. We utilized the elasticity probe, which measured the skin’s 
elasticity, viscoelasticity, and retraction time, the hydration probe, which measured epidermal 
hydration, and the ultrasound probe, which measured dermal thickness and collagen intensity. We 
adjusted these measurements to account for age-related differences and compared our findings 
among our cases and controls.  
3.2.1 HUMAN SUBJECTS 
All the participants in this study gave their informed consent for participation in a study examining 
the etiology and natural history of connective tissue disorders, specifically cutis laxa and related 
disorders including ATS. All procedures were approved by the Institutional Review Board of the 
University of Pittsburgh’s Office for the Protection of Human Subjects in Research (Appendix A). 
Individuals were eligible to participate in this study if possessed a clinical diagnosis of 
arterial tortuosity or had a first-degree relative who had arterial tortuosity (Appendix B). 
Participants in this study were recruited and consented in person at the 2017 Arterial Tortuosity 
Syndrome Annual Conference in Little Rock, Arkansas held by A Twist of Fate-ATS (ATOF). 
We obtained self-reported ages, genetic information, and family history of participants or from the 
adult parents of minor participants through. We performed a variety of skin measurements using 
the DermaLab® Combo SkinLab on each participant as described below. 
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3.2.2 BIOMECHANICAL SKIN MEASUREMENTS - DERMALAB® 
The DermaLab® Combo is an instrument devised to perform rapid, non-invasive, in vivo 
measurements of skin properties. DermaLab® modules have been validated by multiple studies 
since its introduction by Cortex Technology thirty years ago.48 All described measurements of the 
skin were evaluated on four areas of interest - the right dorsal forearm, the right ventral forearm, 
the left ventral forearm, and the left dorsal forearm - approximately halfway between the wrist and 
the elbow on each participant, as shown in Figure 2. Combined, measurements take approximately 
fifteen minutes to complete. 
 
Figure 2. Right arm areas of interest for measurement 
3.2.2.1 ELASTICITY 
The DermaLab® elasticity module uses a suction chamber applied to the skin using a two-sided 
adhesive tape ring. It measures the viscoelastic properties of the skin by measuring the stress/strain 
required to elevate the skin a standardized height of 1.5 mm, where stress/strain is the force per 
unit area within the skin due to external influence. Elastic modulus (E) is then used to reflect the 
relationship between the distensibility and elasticity of the skin, specifically stress over strain and 
is calculated by dividing the change in pressure applied by the change in elevation of the skin, 
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multiplied by the assumed constant skin thickness. Thus, the provided E in megapascals (MPa) is 
an indication of the elasticity of the measured skin, with a high E being indicative of stiffer, more 
sclerotic, or overall less extensible skin while a low modulus indicates stretchy, pliable skin.48 
When measuring elasticity, the DermaLab® also measures retraction time, the amount of time 
required for the elevated skin to return to its baseline when applied pressure is removed. This 
value, measured in seconds, is another indicator for the elastic properties of the skin.55 A longer 
retraction time is indicative of inelastic, more viscous skin. A viscoelastic modulus (VE) is also 
calculated using these elasticity and retraction time measurements.9 In this study, five consecutive 
rounds of applied pressure/retraction were performed on each area of interest: right forearm, right 
outer arm, left forearm, and left outer arm.  
 
Figure 3. Elasticity probe 
3.2.2.2 HYDRATION 
The DermaLab® hydration module utilizes a conductance measurement to determine the water 
content of the stratum corneum via eight pin electrodes reported in the units of micro Siemens 
(uS), a measure of electrical conductance. The higher the conductance, the greater the epidermal 
hydration.53 In this study, two readings were obtained for each area of interest by placing the probe 
firmly against the skin. 
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Figure 4. Hydration pin probe 
3.2.2.3 ULTRASOUND 
The DermaLab® ultrasound module contains a rotating ultrasound sensor probe with a center 
frequency of 20 mega Hertz to instantly measure collagen intensity and assess the thickness of the 
dermis by delineating the border between the epidermis, the dermis, and the subcutaneous fat 
tissue.56 Outputs include collagen density measure in megapascals (MPa) and skin thickness 
measured in millimeters (mm). The image output is also available for analysis. The module is 
prepared by filling the ultrasound chamber with water, which serves as the conductor, and then 
covering the water with film, which is placed against the skin covered with a small amount of 
ultrasound gel. In this study, ultrasound imaging was performed on each area of interest. 
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Figure 5. Ultrasound probe 
3.2.3 STATISTICAL ANALYSIS 
The collected measurements were combined for analysis. The multiple readings of each parameter 
were averaged and the left and right arm readings for each arm were also averaged to provide a 
single ventral and dorsal measurement for each parameter. Thus, data was analyzed to look for 
statistically significant differences between cases and controls, separately for inner and outer arm. 
The rationale for separate analysis of the ventral and dorsal measurements is that the dorsal arm is 
generally more exposed to the sun. Sun damage is a major factor in the age-related deterioration 
of the skin mechanics.57 All statistical analysis was performed using R software. 
The Shapiro-Wilkes test for normality was performed on each parameter to ensure a normal 
distribution for further analysis. All properties were normally distributed, except for retraction time 
which was skewed right on both dorsal and ventral measurements. Chi-squared tests were 
performed on the categorical age and sex demographic date and t-tests were used for the 
continuous biomechanical property data. Pearson’s correlations were calculated between age and 
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each biomechanical property, excluding retraction time, for which Spearman’s test was used. 
Linear regression was utilized to correct each parameter for the confounding factor of age. 
3.3 RESULTS 
The participants in this study included eight individuals affected with ATS and utilized twenty-
one of their unaffected relatives as controls. While sex distribution was not statistically significant 
between cases and controls, the population affected with ATS was significantly younger than 
controls (Table 1). The ages of the cases ranged from 6 years of age to 56 years of age while the 
ages of the controls ranged from 9 years old to 69 years old. All of our participants were Caucasian. 
Table 1. Participant demographics 
 Affected (n=8) Unaffected (n=21) P-value 
Age 16.1 ± 6.6 years 36.2 ± 4.2 years 0.009 (t-test) 
Sex (% male) 63.5% 42.9% 0.793 (Chi-squared) 
 
Four of our eight affected individuals reported mutation status by providing copies of 
previous genetic testing reports. All of these participants were compound heterozygotes for 
SLC2A10 pathogenic variants, with the known recurrent c.394C>T or p.Arg132Trp mutation 
being the most frequently observed among participants occurring in two of the cases (Table 2). 
We also included four individuals of unknown SLC2A10 genotype by self-report, although three 
of them report undergoing genetic testing and having a molecular diagnosis. One affected 
participant had been clinically but not molecularly diagnosed. 
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Table 2. Known SLC2A10 genotypes of cases 
 Mutation One Mutation Two 
Reference Sequence Nucleotide Amino Acid Nucleotide Amino Acid 
NM_030777.3 c.394C>T p.R132W c.4+5G>A NA 
NM_030777.3 c.314C>T p.R105H c.727C>A p.Q234K 
NM_030777.3 c.394C>T p.R132W c.800delC NA 
NM_030777.3 c.848C>A p.A283D c.2381G>A p.R794H 
 
Pearson and Spearman tests were performed to determine the correlation of each cutaneous 
measure with age (Table 3). Dermal hydration, collagen intensity, and VE were negatively 
correlated with increasing age while dermal thickness and retraction time were positively 
correlated with age. The only statistically significant correlations were between age and the 
collagen intensity measured on the dorsal forearm and between age and the retraction time 
measured on the dorsal forearm. This suggests that age truly has an effect on collagen density, 
more so on the dorsal forearm than the ventral forearm, as well as on retraction time, again more 
so on the dorsal forearm than the ventral forearm.  
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Table 3. Correlation of age and parameters 
 Ventral Forearm Dorsal Forearm 
Correlation  P-value  Correlation  P-value 
Elastic modulus (MPa) 0.157 0.415 0.143 0.461 
Viscoelastic modulus (MPa) -0.320 0.0903 -0.432 0.0193 
Retraction Time (s) * 0.380 0.0421 0.575 0.00111 
Hydration (µS) -0.0622 0.749 -0.252 0.188 
Skin Thickness (mm) 0.303 0.124 0.253 0.212 
Collagen Intensity (MPa) -0.408 0.0348 -0.608 0.000979 
*Spearman’s method 
 
Before performing regression analysis to correct for the age differences in the data set, t-
tests were performed on the means of each parameter to identify differences between cases and 
controls. Cases exhibited significantly lower E (ventral p-value = 0.0005513, dorsal p-value = 
0.00582) than controls. Cases also exhibited significantly increased dorsal forearm collagen 
intensity (p-value 0.04646), although the same statistically significant difference was not noted on 
the ventral forearm. No other parameter was significantly different between cases and controls, 
although there were trends among the dataset. Cases exhibited reduced viscoelastic modulus (VE), 
increased hydration, reduced dermal thickness, and increased collagen intensity when compared 
to controls (Table 4, Table 5, Figure 6, Figure 7).  
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Table 4. Biomechanical properties of the ventral forearm 
 Ventral Forearm 
 Affected Unaffected P-vale 
Elastic modulus (MPa) 3.777 ± 0.2 4.342 ± 0.2 0.000551 
Viscoelastic modulus (MPa) 7.533 ± 0.8 8.4747 ± 1.1 0.324 
Retraction Time (s) 132.8 ± 9.7 132.6 ± 9.7 0.984 
Hydration (µS) 119.6 ± 22.3 112.803 ± 13.9 0.619 
Skin Thickness (mm) 979.3 ± 180.0 1024.2 ± 145.1 0.574 
Collagen Intensity (MPa) 58.50 ± 12.0 53.19 ± 8.6 0.385 
 
 
Figure 6. Scatterplot of the ventral elastic modulus data 
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Table 5. Biomechanical properties of the dorsal forearm 
 Dorsal Forearm 
 Affected Unaffected P-value 
Elastic modulus (MPa) 3.959 ± 0.3 4.411 ± 0.1 0.00582 
Viscoelastic modulus (MPa) 7.371 ± 0.9 8.236 ± 0.9 0.304 
Retraction Time (s) 139.0 ± 16.5 152.8 ± 24.7 0.523 
Hydration (uS) 92.78 ± 17.7 89.32 ± 11.7 0.760 
Skin Thickness (mm) 1009.8 ± 311.2 1262.1 ± 219.5 0.534 
Collagen Intensity (MPa) 37.04 ± 6.8 34.12 ± 5.6 0.0464 
 
 
Figure 7. Scatterplot of the dorsal elastic modulus data 
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Linear regression analysis was then performed on each parameter to adjust for the known 
confounding factor of age, as age was shown to be statistically significant between cases and 
controls. Cases exhibited significantly lower E (ventral p-value = 0.0005513, dorsal p-value = 
0.00582) and VE (ventral p-vale = 0.02107, dorsal p-value = 0.003055) than controls. No other 
parameter was significantly different between cases and controls. The trends previously noted 
among the other parameters were not static. Cases exhibited reduced dorsal dermal thickness, but 
ventral dermal thickness was increased over controls. Also, cases demonstrated increased dorsal 
collagen intensity when compared to controls but decreased ventral collagen intensity (Table 6 and 
Table 7). Cases also exhibited increased skin retraction time, which had not been previously 
apparent prior to linear regression (Table 6 and Table 7). When adjusted for age, the epidermal 
hydration remained increased in the affected population on the ventral forearm, but was lower in 
the affected population compared to the unaffected population on the dorsal forearm (Table 6 and 
Table 7). 
Table 6. Age-adjusted biomechanical properties of the ventral forearm 
 Ventral Forearm 
 Affected Unaffected P-value 
Elastic modulus (MPa) 3.852 ± 0.2 4.515 ± 0.2 0.0005 
Viscoelastic modulus (MPa) 8.635 ± 1.0 11.005 ± 1.0 0.021 
Retraction Time (ms) 120.9 ± 8.4 105.2 ± 8.5 0.073 
Hydration (µS) 120.1 ± 15.9 113.9 ± 16.1 0.703 
Skin Thickness (mm) 925.9 ± 88.5 907.6 ± 90.2 0.838 
Collagen Intensity (MPa) 63.83 ± 6.5 64.84 ± 6.6 0.878 
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Table 7. Age-adjusted biomechanical properties of the dorsal forearm 
 Dorsal Forearm 
 Affected Unaffected P-value 
Elastic modulus (MPa) 4.013 ± 0.2 4.535 ± 0.2 0.00659 
Viscoelastic modulus (MPa) 8.613 ± 0.8 11.09 ± 0.8 0.00306 
Retraction Time (ms) 106.6 ± 19.3 78.25 ± 19.5 0.154 
Hydration (µS) 99.65 ± 12.8 105.1 ± 13.0 0.674 
Skin Thickness (mm) 1071.3 ± 198.6 1079.7 ± 189.8 0.966 
Collagen Intensity (MPa) 46.79 ± 3.9 43.95 ± 3.8 0.471 
 
 While our cases ranged in age from 6 years to 56 years, the average age of the cases was 
16.1 years and the median age of the cases was 11 years. The 56-year-old case was the only 
participant affected with ATS over the age of 20. This individual was also the only case that did 
not possess a molecular diagnosis in addition to a clinical diagnosis. We performed a sensitivity 
analysis removing this case from the data set and repeating analysis to account for the possibility 
that this individual’s findings may have had a disproportionate effect on our findings. The 
differences in retraction time between cases and controls was statistically significantly (ventral p-
value 0.0482, dorsal p-value 0.00449) after this participant was removed from analysis (Table 8 
and Table 9). The contradictory trends seen in epidermal hydration and collagen intensity resolved, 
with cases now demonstrating both slightly reduced hydration and slightly reduced collagen 
intensity when compared to controls, although this difference continued to not be significant 
(Table 8 and Table 9). The contradictory trends between dorsal and ventral dermal thickness 
persisted (Table 8 and Table 9). 
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Table 8. Age-adjusted biomechanical properties of the ventral forearm with outlier removed 
 Ventral Forearm 
 Affected Unaffected P-value 
Elastic modulus (MPa) 4.23 ± 0.2 4.70 ± 0.2 0.000057 
Viscoelastic modulus (MPa) 8.50 ± 1.1 11.80 ± 1.1 0.00611 
Retraction Time (ms) 121.58 ± 9.9 101.11 ± 9.6 0.0482 
Hydration (µS) 118.50 ± 18.7 122.90 ± 18.1 0.815 
Skin Thickness (mm) 930.35 ± 105.64 872.32 ± 103.92 0.588 
Collagen Intensity (MPa) 63.08 ± 7.3 71.32 ± 7.2 0.268 
 
Table 9. Age-adjusted biomechanical properties of the dorsal forearm with outlier removed 
 Dorsal Forearm 
 Affected Unaffected P-value 
Elastic modulus (MPa) 3.98 ± 0.2 4.74 ± 0.2 0.000476 
Viscoelastic modulus (MPa) 8.49 ± 0.8 11.82 ± 0.8 0.000596 
Retraction Time (ms) 108.20 ± 22.8 68.9651 ± 22.1 0.00449 
Hydration (µS) 99.01 ± 15.3 108.1 ± 14.9 0.674 
Skin Thickness (mm) 1059.5 ± 327.2 1075.6 ± 222.1 0.947 
Collagen Intensity (MPa) 46.21 ± 4.6 46.67 ± 4.3 0.923 
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3.4 DISCUSSION 
In this study, we evaluated elastic modulus (E), viscoelastic modulus (VE), and retraction time as 
well as epidermal hydration, dermal thickness, and collagen intensity among individuals affected 
with ATS. We hypothesized that individuals with ATS would exhibit differences in these 
properties when compared with their unaffected relatives, namely reduced E, VE, and dermal 
thickness with increased retraction time, epidermal hydration, and collagen intensity. Our sample 
consisted of eight individuals clinically diagnosed with ATS ranging in age from 6 years old to 56 
years old. Of these eight individuals, seven have been molecularly diagnosed with biallelic 
SLC2A10 pathogenic variants. Of note, one affected individual was significantly older than the 
other affected individuals at 56 years of age and this participant was the one case that did not have 
a molecular diagnosis confirming biallelic SLC2A10 pathogenic variants. Twenty-one unaffected 
relatives of our affected participants ranging in age from 9 years old to 69 years old were used as 
our healthy control group.  
Our affected population exhibited significantly lowered elastic modulus (E) compared to 
the unaffected population. Age is not expected to significantly influence skin elasticity until the 
age of 70,58,59 which was reflected in the lack of correlation of E and participant age in our data 
set. This finding was particularly robust, as the difference in E was maintained when adjusted for 
age as well as when the outlier was removed from analysis. Cases also exhibited reduced 
viscoelastic modulus (VE) when compared to healthy controls. Correlation between age and VE 
was statistically significant on the dorsal forearm, which was reflected in the difference in VE 
becoming statistically significant after age-adjustment was performed. This difference was 
maintained when the outlier was removed from analysis. The correlation between age and 
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retraction time was also statistically significant, both dorsally and ventrally. Cases exhibited 
increased retraction time compared to controls when the outlier was removed from analysis.  
The skin of individuals affected with ATS was described as hyperextensible,11 consistent 
with our results in reduced E and VE. Qualitative observations also noted that ATS skin returned 
to baseline without issue.11 Our quantitative results, however, do show that the amount of time 
required for the skin to retur to baseline is increased over individuals without ATS, indicating that 
the sensitivity to detect alterations in skin mechanics in quantitative measurements is higher than 
the sensitivity of qualitative observations. Taken together, reduced E and VE with increased 
retraction time are all consistent findings with dysregulation of the extracellular matrix affecting 
typical biomechanical functioning of the skin.  
Previous studies investigated the biomechanics of two elastic fiber disorders, cutis laxa9 
and Williams syndrome8,46 with similar findings to our results in ATS. In cutis laxa (CL), affected 
individuals also demonstrate reduced E and VE and increased retraction time.9 However, the 
increased retraction time demonstrated in our cases was not as robust as in CL, and the magnitude 
of increase in mean retraction time relative to controls was uch less in ATS (20 ms, 20%) than in 
CL (530 ms, 85%), consistent with more severely inelastic skin in CL than in ATS. In studies 
examining biomechanical skin properties in Williams syndrome, affected individuals exhibited 
reduced E and VE with about the same effect size as our observations in ATS, but no significant 
difference was found in the retraction time of individuals with Williams syndrome.8 Therefore, 
our findings suggest a skin phenotype in ATS that is less severe than CL, and the same or slightly 
more severe than Williams syndrome. Given the prior evidence of altered alstic fiber structure and 
function in all three diseases, we can conclude that the reduction of E and VE with a possible 
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additional increase RT are shared characteristics of a skin phenotype caused by genetic disorders 
of elastic fibers. 
Our affected participants did not demonstrate a significant difference in epidermal 
hydration compared to the unaffected group. Currently there are no reports in the literature that 
measured hydration in related connective tissue disorders. However, a mouse model of autosomal 
recessive CL 1C (ARCL1C, also known as LTBP4-related CL) did show increased epidermal 
hydration, which was interpreted as a signed of impaired skin barrier function.60 The lack of 
significant and consistent change in epidermal hydration in our affected participants supports the 
conclusion that the epidermal barrier function is preserved in ATS. 
We predicted that individuals with ATS would have reduced thickness based on findings 
of other connective tissue disorders, namely Ehlers-Danlos syndrome, in which affected 
individuals are often reported to have thin, fragile, and translucent skin.61 However, we did not 
observe a significant difference in this parameter. These findings correlate with the phenotype of 
ATS, which does not suggest markedly different skin thickness in individuals affected with ATS. 
There have not been reports of thin skin with visible vessels or easy bruising. 
Finally, we predicted that individuals with ATS may exhibit increased collagen intensity 
due to a recent study reporting that individuals with ATS experience increased collagen deposition 
in their arteries.1 While the mechanism of increased collagen deposition is not well understood, 
general dysregulation of the extracellular matrix has already been implicated in ATS. Moreover, 
increased collagen deposition has been implicated in thoracic aortic dissection due to collagen’s 
rigidity lending to reduced aortic distensibility.62 In this study, the affected population did not 
exhibit significantly different collagen intensity compared to the unaffected population, which may 
reflect tissue-specific differences in collagen deposition. 
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This study has several limitations. First, there are limitations based upon our chosen 
instrument, the DermaLab® Combo SkinLab. This instrument assumes a uniform skin thickness 
of 1 mm when calculating the elasticity modulus and viscoelastic modulus. This research did not 
identify a significant difference in skin thickness, which suggests that E and VE would not have 
been significantly impacted by this issue. 
Additionally, due to the small number of affected individuals in our sample, our results 
must be confirmed in a larger control sample size. Due to restraints from our study protocols, we 
were unable to collect measurements on individuals who are not related to an affected proband. 
However, at this time, unaffected carriers of ATS are not known to exhibit clinical findings of 
ATS and are considered asymptomatic.11 The relatedness of the cases and controls may have 
influenced the results of this study due to yet unknown heritable contribution to the parameters 
tested. In future studies, genotyping unaffected individuals will be important. Finally, due to the 
nature of our study procedures as well as the severity of ATS, our cases were significantly younger 
than our controls. A larger sample, with unrelated cases and controls as well as significantly 
younger controls to match case age, would also allow for expanded analysis of results, including 
comparing the different skin properties to identify relationships and determining which feature 
possesses the strongest indication for the presence of ATS. Other avenues for future research 
include examining genotype-phenotype relationships between specific mutations and cutaneous 
properties. Despite the presence of several recurrent mutations within the ATS population, no 
genotype-phenotype correlations have been elucidated.11  
We would like to compare the results of this study to other research performed in our 
laboratory examining biomechanical properties of the skin in the related connective tissue disorder 
cutis laxa. Our previous research was limited to elasticity, viscoelastic modulus, and retraction 
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time but has recently expanded to include all the parameters measured in this study.9 Examining 
differences between individuals affected with ATS, individuals affected with CL, and healthy 
controls may further elucidate phenotypic differences not only between individuals with a 
connective tissue disorder and healthy controls, but also between different connective tissue 
disorders. This may be expanded to compare to other connective tissue disorders, for example, 
these skin characteristics have also been studied in Williams syndrome.8 
3.5 CONCLUSIONS 
Among our participants, individuals with ATS exhibited significantly reduced cutaneous elastic 
modulus and viscoelastic modulus when compared to their unaffected relatives. The skin of 
affected individuals also demonstrated increased retraction time. The differences in epidermal 
hydration, dermal thickness, and collagen intensity between populations were not significantly 
different between affected and unaffected individuals. While this interpretation is limited by both 
the small sample size as well as the relatedness of our cases and controls, biomechanical and other 
quantifiable skin properties have never been characterized in this rare connective tissue disorder. 
These results have the potential to aid in diagnosis and management of the ATS population. 
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4.0  RESEARCH SIGNIFICANCE TO PUBLIC HEALTH AND GENETIC 
COUNSELING 
Rare diseases are defined in the United States as conditions that affect fewer than 200,000 
individuals.63 These conditions like ATS profoundly impact the lives of affected individuals and 
their family members. While the number of affected individuals may be small within each rare 
disease, around ten percent of Americans are affected by one of 7,000 defined conditions classified 
as a rare disease.64 That is, individually, rare diseases may not appear to be a large component of 
public health, but taken together, these diseases affect a significant percent of individuals living in 
the United States. 
The ten essential public health services certainly apply to rare diseases. Both the diagnosis 
of disease and ensuring that affected individuals are linked with trained specialists are particularly 
applicable.65 Studies that learn more about the etiology and natural history of rare diseases improve 
our overall understanding of these conditions in an effort to better diagnose and enhance our ability 
to treat them.66 The results of this study help us identify additional phenotypic features of ATS, 
particularly in determining phenotypic variation among affected individuals. Increasing our 
understanding of the cutaneous features of ATS can aid in future diagnosis of affected individuals, 
especially because ATS is likely both underdiagnosed and misdiagnosed in the general 
population.5 The issue of proper diagnosis is especially prevalent within the rare disease 
community. Often, patients who suffer from rare diseases undergo an extended period of time 
during which they are experiencing symptoms but have yet to be diagnosed, a journey so 
characteristic of rare diseases that this period has been named the diagnostic odyssey.67  
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The instrument used in this study, the DermaLab® Combo SkinLab, has been verified by 
several different projects for several different genetic disorders. By continuing to define its 
abilities, this instrument may one day move from a purely research-based application to 
widespread use in clinical practice with the ability to aid in the diagnosis of complex connective 
tissue disorders. Early, accurate diagnosis aids not only in early implementation of management, 
but also allows health care practitioners, including genetic counselors, to identify other family 
members at risk, provides relief to the patient and family, and offers the opportunity for these 
individuals to join disease support networks.63  
Implementation of management ensures that affected individuals receive appropriate 
medical treatment by trained specialists. ATS, like many other genetic disorders, is often treated 
by a multidisciplinary team to address the significant cardiovascular issues as well as the variable 
other systemic features, including skeletal, ocular, and craniofacial. This treatment approach has 
been utilized not only among other connective tissue disorders similar to ATS,68,69 but widely 
across genetic disorders due to their complex and systemic nature. This study’s contribution to the 
definition of ATS’s phenotype allows for the appropriate specialists, including dermatologists and 
genetic counselors, to be included on these individuals care team. Genetic counselors are uniquely 
skilled individuals who can guide individuals through a diagnosis of a genetic disease, including 
shortening an individual’s diagnostic odyssey as well as providing anticipatory guidance once a 
diagnosis has been provided. Once a rare disease has been better defined, elucidating the etiology 
of a rare disease can further guide diagnosis and provides an avenue for the development of 
targeted therapies.  
Additionally, while the systemic tortuosity of ATS is rare, isolated arterial kinking is more 
common in the population and may often be reported as a benign finding upon imaging with 
  39 
increasing tortuosity increasingly indicative of pathology.70 Isolated arterial tortuosity has been 
described in nearly all vessel branches in the body with aging, hypertension, atherosclerosis, and 
diabetes mellitus.71 Arterial tortuosity has also been described in patients with sickle cell disease72 
and has been implicated in cases of pediatric arterial ischemic stroke.73  The cardiovascular 
outcomes of arterial tortuosity syndrome are also more common in the general population. Due to 
risk factors like tobacco use and hypertension, aneurysm occurs in around one in fifty individuals 
in the United States. Gaining a deeper understanding about the etiology of both arterial tortuosity 
and the cardiovascular outcomes associated with ATS will allow for wider understanding of these 
phenomena in the general population. 
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APPENDIX C: SUPPLEMENTARY DATA 
Figure 8. Scatterplot of dorsal viscoelasticity data 
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Figure 9. Scatterplot of ventral viscoelasticity data 
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Figure 10. Scatterplot of dorsal epidermal hydration data 
Figure 11. Scatterplot of ventral epidermal hydration data 
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Figure 12. Scatterplot of dorsal dermal thickness data 
Figure 13. Scatterplot of ventral dermal thickness data 
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Figure 14. Scatterplot of dorsal collagen intensity data 
Figure 15. Scatterplot of ventral collagen intensity data 
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Table 10. Ventral retraction time 
Affected Unaffected P-value
RT1 129.6 ± 7.8 128.0 ± 8.2 0.83 
RT2 130.6 ± 8.7 130.1 ± 9.3 0.95 
RT3 132.5 ± 9.7 133.4 ± 10.6 0.93 
RT4 134.6 ± 10.8 136.4 ± 12.3 0.87 
RT5 136.7 ± 11.9 135.3 ± 10.0 0.88 
Figure 16. Scatterplot of ventral retraction time data 
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Table 11. Dorsal retraction time 
Affected Unaffected P-value
RT1 131.3 ±8.3 137.0 ± 13.7 0.63 
RT2 133.8 ± 11.5 144.0 ± 18.9 0.53 
RT3 138.3 ± 16.1 152.4 ± 24.1 0.50 
RT4 143.3 ± 21.3 161.1 ± 30.2 0.50 
RT5 148.6 ± 27.1 169.4 ± 36.9 0.52 
Figure 17. Scatterplot of dorsal retraction time data 
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Table 12. Ventral RT percent change 
Affected Unaffected P-value
Percent Change 1 0.63 ±1.3 1.4 ± 0.78 0.33 
Percent Change 2 1.4 ± 1.1 2.2 ± 0.75 0.25 
Percent Change 3 1.5 ± 0.8 1.9 ±0.92 0.63 
Percent Change 4 1.4 ± 0.8 -0.80 ± 5.0 0.60 
Table 13. Dorsal RT percent change 
Affected Unaffected P-value
Percent Change 1 1.5 ± 3.2 3.5 ± 2.1 0.30 
Percent Change 2 2.7 ± 2.7 4.2 ± 1.6 0.38 
Percent Change 3 2.8 ± 2.6 3.8 ± 1.7 0.54 
Percent Change 4 2.8 ± 2.5 3.2 ± 1.6 0.80 
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